These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 14655309)

  • 21. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Femoral Arterial Hemostasis using the Angio-Sealª System after Coronary and Vascular Percutaneous Angioplasty and Stenting.
    Cremonesi A; Castriota F; Tarantino F; Troiani E; Ricci E; El Jamal B ; Grattoni C; Noera G
    J Invasive Cardiol; 1998 Oct; 10(8):464-469. PubMed ID: 10762823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
    Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
    Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
    Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
    Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
    Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
    Kereiakes DJ; Grines C; Fry E; Esente P; Hoppensteadt D; Midei M; Barr L; Matthai W; Todd M; Broderick T; Rubinstein R; Fareed J; Santoian E; Neiderman A; Brodie B; Zidar J; Ferguson JJ; Cohen M;
    J Invasive Cardiol; 2001 Apr; 13(4):272-8. PubMed ID: 11287711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions.
    Best PJ; Lennon R; Gersh BJ; Ting HH; Rihal CS; Bell MR; Herzog CA; Holmes DR; Berger PB
    Am Heart J; 2003 Aug; 146(2):345-50. PubMed ID: 12891206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of femoral vascular closure devices in patients treated with anticoagulant, abciximab or thrombolytics during percutaneous endovascular procedures.
    Kim HY; Choo SW; Roh HG; Han H; Kim SS; Lee JY; Park YR; Lee SH; Shin SW; Park KB; Do YS; Cho SK; Lee IH; Kim SM; Byun HS; Jeon P
    Korean J Radiol; 2006; 7(1):35-40. PubMed ID: 16549954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vascular complications at the femoral access: impact of the percutaneous closure device Perclose].
    Mboup MC; Moquet B; Zabalawi A; Delaunay R
    Ann Cardiol Angeiol (Paris); 2014 Apr; 63(2):71-4. PubMed ID: 24613004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of a 6 French perclose arterial suturing device following percutaneous coronary interventions: a pilot evaluation.
    Kornowski R; Brandes S; Teplitsky I; Rechavia E; Shor N; Battler A; Assali A
    J Invasive Cardiol; 2002 Dec; 14(12):741-5. PubMed ID: 12454337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of a combination of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomized pilot study].
    Galeote G; Hussein M; Sobrino N; Calvo L; Sánchez-Recalde A; Sobrino JA
    Rev Esp Cardiol; 2002 Dec; 55(12):1261-6. PubMed ID: 12459075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?
    Sharma S; Makkar R; Lardizabal J
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):136-41. PubMed ID: 16891291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ReoPro Observational Registry (RAPOR): insights from the multicentre use of abciximab in Asia.
    Poh KK; Tan HC; Yip JW; Lim YT
    Singapore Med J; 2005 Aug; 46(8):407-13. PubMed ID: 16049611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of abciximab use in MCO and non-MCO populations.
    Lage MJ; Barber BL; Bala M; Ball DE; Bowman L
    Am J Manag Care; 2001 Jan; 7(1):53-62. PubMed ID: 11209450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective randomized trial comparing the safety and efficacy of three commercially available closure devices (Angioseal, Vasoseal and Duett).
    Michalis LK; Rees MR; Patsouras D; Katsouras CS; Goudevenos J; Pappas S; Sourla E; Kolettis T; Sioros L; Zotou P; Gartzou-Matsouka P; Sideris DA
    Cardiovasc Intervent Radiol; 2002; 25(5):423-9. PubMed ID: 12132030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brachial artery perforation repaired with percutaneous transfemoral covered stent deployment in a patient on abciximab.
    Kelly D; Levy T; Talwar S
    J Invasive Cardiol; 2008 Mar; 20(3):E82-3. PubMed ID: 18316839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.